25.06.2012 • News • Lonza • BioWa • cell culture

Lonza, Biowa Sign License Agreements with FivePrime Therapeutics

FivePrime Therapeutics has entered into research and commercial agreements with Biowa and Lonza to use their Potelligent CHOK1SV Cell Line for the research, development and production of multiple proprietary antibodies in FivePrime's oncology pipeline.

Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of Biowa's engineered glycosylation Potellingent Technology with the advantages of Lonza's proprietary GS Gene Expression Systems, which includes the industry-leading CHOK1SV cell line.

 

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Top-Feature

most read